Moleculin Biotech Financials - Benzinga

Moleculin Biotech Inc

MBRXNASDAQ

Trade with Public

Trade with Public

$0.6548

0.00490.75%

Ult. Agg.: Aug 31, 1:20 PM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Rapporto azionario

Moleculin Biotech Financials

Moleculin Biotech (MBRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share

Benzinga Newsdesk

PRO
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses of $(15.80) per share

Benzinga Newsdesk

PRO
Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over losses of $(9.25) per

Benzinga Newsdesk

Nasdaq Surges 100 Points; Dollar General Earnings Beat Views

Avi Kapoor

US Stocks Mixed; Nvidia Posts Upbeat Earnings

Avi Kapoor

PRO
Moleculin Biotech Q2 EPS $(0.49) Misses $(0.42) Estimate

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.42) by 16.67 percent. This is a 71.18 percent increase over losses of $(1.70) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved